Chimeric antigen receptor (CAR) T-cell therapy has shown impressive responses in patients with heavily pretreated multiple myeloma. An open and tra......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
While the ability to treat patients with highly refractory multiple myeloma is promising, a great need remains for novel agents and additional ther......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
With the ultimate goal of having a cure for multiple myeloma, researchers and clinicians hope to assemble strategies that will incorporate new and ......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
Chimeric antigen receptor (CAR) T-cell therapy can achieve very high response rates in heavily pretreated multiple myeloma, allowing many patients ......READ MORE
The management of multiple myeloma is evolving with the emergence of new agents and new approaches to treatment. The paradigm is shifting in severa......READ MORE
High-risk and ultra-high-risk multiple myeloma, characterized by the presence of cytogenetic abnormalities and/or extramedullary disease, represent......READ MORE
